Detected ·
Orakl Oncology
€30MSeries A
Orakl Oncology, a Paris-based AI-supported cancer drug development company, raised €30 million ($34 million) in an oversubscribed Series A co-led by Norrsken VC and Singular.
- Website
- —
- linkedin.com/company/85957194
- Amount
- €30 000 000 EUR
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-13 12:07:27 UTC
- Signal ID
- e7c340a8-a64d-4fb8-946b-57698df30c9b
As the API returns it
{
"id": "e7c340a8-a64d-4fb8-946b-57698df30c9b",
"created_at": "2026-11-13T12:07:27.653002Z",
"company_name": "Orakl Oncology",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/85957194",
"event_type": "funding",
"funding_amount": 30000000,
"funding_currency": "EUR",
"funding_stage": "series_a",
"message": "*Orakl Oncology, a Paris-based AI-supported cancer drug development company, raised €30 million ($34 million) in an oversubscribed Series A co-led by Norrsken VC and Singular.*"
}